Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Pipeline Review, H2 2016

Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Pipeline Review, H2 2016
Published Jul 30, 2016
64 pages — Published Jul 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Pipeline Review, H2 2016, provides in depth analysis on Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) targeted pipeline therapeutics.

The report provides comprehensive information on the Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1)
- The report reviews Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Trans

  
Source:
Document ID
GMDHC0433TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Overview71
Therapeutics Development84
  Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Products under Development by Stage of Development81
  Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Products under Development by Therapy Area91
  Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Products under Development by Indication102
Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Pipeline Products Glance122
  Late Stage Products121
  Early Stage Products131
Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Products under Development by Companies142
Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Products under Development by Universities/Institutes162
Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Therapeutics Assessment186
  Assessment by Monotherapy/Combination Products181
  Assessment by Mechanism of Action192
  Assessment by Route of Administration212
  Assessment by Molecule Type231
Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Companies Involved in Therapeutics Development248
  AnaBios Corporation241
  Astellas Pharma Inc.251
  AstraZeneca Plc261
  Flex Pharma, Inc.271
  Glenmark Pharmaceuticals Ltd.281
  Hydra Biosciences, Inc.291
  Johnson &Johnson301
  Pila Pharma AB311
Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Drug Profiles3218
  ASP-7663 Drug Profile321
  AZ-465 Drug Profile331
  FLX-787 Drug Profile344
  GRC-17536 Drug Profile382
  HX-100 Drug Profile402
  hydralazine hydrochloride Drug Profile421
  JNJ-41477670 Drug Profile431
  Small Molecule to Antagonize TRPA-1 for Pain And Respiratory Disorders Drug Profile441
  Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia Drug Profile451
  Small Molecules to Block TRPA1 and TRPV1 for Central Nervous System Drug Profile462
  Small Molecules to Block TRPA1 and TRPV1 for Pain Drug Profile481
  Small Molecules to Block TRPA1 and TRPV1 for Pain and Inflammation Drug Profile491
Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Dormant Projects501
Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Discontinued Products511
Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Featured News &Press Releases5211
  Jun 15, 2016: Flex Pharma Initiates Phase 2 Efficacy Study in Multiple Sclerosis521
  May 25, 2016: Flex Pharma Initiates Human Efficacy Study with Single Molecule Tablet in Nocturnal Leg Cramps521
  Apr 19, 2016: Flex Pharma s Positive Human NLC Study Selected for Presentation at AAN Annual Meeting531
  Mar 14, 2016: Flex Pharma Positive Human NLC Study Selected for Late-Breaking Presentation at AAN Annual Meeting541
  Feb 02, 2016: Flex Pharma Announces Positive Human Efficacy in Nocturnal Leg Cramp Study551
  Jan 06, 2016: Hydra Biosciences to Present at the 8th Annual Biotech Showcase Conference in San Francisco on Jan. 11561
  Jan 06, 2016: Enrollment Completed in Flex Pharma s Exploratory Human Nocturnal Leg Cramp Study561
  Nov 10, 2015: Flex Pharma Announces FLX-787 as Clinical Drug Candidate571
  Oct 20, 2015: Flex Pharma Demonstrates Single Agent Efficacy and Dose Response in Reducing Human Muscle Cramps581
  Jul 28, 2015: Flex Pharma Announces Two Poster Presentations at Upcoming Scientific Meetings581
  Jul 07, 2015: Flex Pharma Announces Reduction of Muscle Cramping in Athletes591
  May 04, 2015: NSF Approves Flex Pharma s Proprietary Formulation under NSF s Certified for Sport Program601
  Apr 27, 2015: Flex Pharma Initiates Human Proof-of-Concept Efficacy Study in Nocturnal Leg Cramps601
  Apr 14, 2015: Hydra Biosciences Receives Approval from Health Canada to Begin Phase 1 Trial for HX-100611
  Feb 18, 2015: AAN Selects Flex Pharma Data for Oral Platform Presentation612
Appendix632
  Methodology631
  Coverage631
  Secondary Research631
  Primary Research631
  Expert Panel Validation631
  Contact Us631
  Disclaimer641

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Pipeline Review, H2 2016" Jul 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Transient-Receptor-Potential-Cation-Channel-Subfamily-A-Member-1-Ankyrin-Like-With-Transmembrane-Domains-Protein-1-or-Transformation-Sensitive-Protein-p120-or-TRPA1-Pipeline-Review-H2-2016-2088-16331>
  
APA:
Global Markets Direct - Market Research. (2016). Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Pipeline Review, H2 2016 Jul 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Transient-Receptor-Potential-Cation-Channel-Subfamily-A-Member-1-Ankyrin-Like-With-Transmembrane-Domains-Protein-1-or-Transformation-Sensitive-Protein-p120-or-TRPA1-Pipeline-Review-H2-2016-2088-16331>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.